The deal is believed to enforce VistaGen’s stem cell technology-based drug rescue activities using Synterys’ medicinal chemistry expertise. VistaGen’s drug rescue initiatives comprise its human pluripotent stem cell
Pertuzumab, a humanised monoclonal antibody, acts by inhibiting the binding of HER2 receptor from other HER receptors, resulting in suppression of cancer cell growth or lead to the
According to the company, the patent will provide exclusivity for Pulmaquin until 22 October 2027. Pulmaquin is a dual release formulation that is a mixture of a liposomal
Melt Extrusion and Calendering Line will help pharmaceutical manufacturers procure extrusion, calendering and cooling equipment from one supplier, packagingeurope.com reported. Melt extrusion, which is a method for drug
The approval allows the company to use VibeX with its KXL system for treating corneal ectasia. Avedro CEO David Muller said this second orphan drug designation and the
The launch follows a settlement with Teva Women’s Health. The global marketing research company for the pharmaceutical industry, IMS Health said Watson is the first applicant to submit
BOLERO-2 (Breast cancer trials of OraL EveROlimus-2), a Phase III, randomized, double-blind, placebo-controlled, multicenter study was devised to assess the safety and efficacy of everolimus in combination with
Cegedim Relationship Management’s REMS compliance solution includes compliance consulting, customer outreach, data analytics and a campaign management platform. According to the company, REMS are risk management plans that
Organotec specialises in the field of special organic chemical products, fine chemicals and their correlated technologies with main focus on pharmaceutical industry, offering a range of specialised intermediates
On completion of the survey, participants will be able to instantly download key findings from our previous survey research published in Q3 2011 examining sustainability in the pharmaceutical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.